Table 1.

Baseline clinical data of 17 cases of EGFR-mutant lung adenocarcinoma.

Characteristics	MMP11-positive expression group (N=12)	MMP11-negative expression group (N=5)	Total (N=17)	P-value
Gender
Female	5(41.67%)	2(40%)	7(41.18%)	1
Male	7(58.33%)	3(60%)	10(58.82%)
age
≥65	2(20.00%)	1(20%)	3(17.65%)	1
<65	10(80.00%)	4(80%)	14(82.35%)
T stage
T1	1(8.33%)	1(20%)	2(11.76%)	0.88
T2	2(16.67%)	1(20%)	3(17.65%)
T3	2(16.67%)	1(20%)	3(17.65%)
T4	7(58.33%)	2(40%)	9(52.94%)
N stage
N0	6(50%)	2(40%)	8(47.06%)	0.81
N1	4(33.33%)	3(60%)	7(41.18%)
N2	1(8.33%)	0(0%)	1(5.88%)
N3	1(8.33%)	0(0%)	1(5.88%)
M stage
M0	8(66.67%)	2(40%)	10(58.82%)	0.59
M1	4(33.33%)	3(60%)	7(41.18%)